Marker Therapeutics Q2 net loss narrows to $2.2M; reports positive MT-601 APOLLO data, receives $2M NIH grant

Marker Therapeutics, Inc.

2024-Q2 EPS reported -$0.51 revenue$2,413,297

Net loss from continuing ops $2.2M vs $4.1M YoY; cash $7.8M expected to fund into Q4 2025.
MT-601 APOLLO study shows objective responses in 3 of 3 lymphoma patients; no CRS or ICANS observed.
Awarded $2M NIH SBIR grant to support MT-601 lymphoma trial.
MT-401-OTS IND cleared for AML/MDS; clinical program initiation expected Q4 2024.
R&D expenses $2.3M (flat); G&A decreased to $1.1M from $2.5M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.